Evidence map›Paper›PMID 39013115›Full record

ArticleJMIR public health and surveillance2024

Surveillance Metrics and History of the COVID-19 Pandemic in Central Asia: Updated Epidemiological Assessment.

Alexander L Lundberg, Egon A Ozer, Scott A Wu, Alan G Soetikno, Sarah B Welch, Yingxuan Liu, Robert J Havey, Robert L Murphy, Claudia Hawkins, Maryann Mason and 2 more

Abstract readHistorical Article
In one paragraph

Article in JMIR public health and surveillance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Coping with COVID-19 Intensive Care Unit admission.Revista brasileira de enfermagem · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexander L LundbergBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-9743-8441
Egon A OzerDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-7131-3691
Scott A WuFeinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-0440-1218
Alan G SoetiknoFeinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-3404-1671
Sarah B WelchBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-5609-3718
Yingxuan LiuBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-6697-0160
Robert J HaveyRobert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-7176-058X
Robert L MurphyDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-3936-2052
Claudia HawkinsDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-7228-6317
Maryann MasonBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-6524-1532
Chad J AchenbachDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-4847-7249
Lori A PostBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-6261-3254

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study updates the COVID-19 pandemic surveillance in Central Asia we conducted during the first year of the pandemic by providing 2 additional years of data for the region. The historical context provided through additional data can inform regional preparedness and early responses to infectious outbreaks of either the SARS-CoV-2 virus or future pathogens in Central Asia.

objectiveFirst, we aim to measure whether there was an expansion or contraction in the pandemic in Central Asia when the World Health Organization (WHO) declared the end of the public health emergency for the COVID-19 pandemic on May 5, 2023. Second, we use dynamic and genomic surveillance methods to describe the history of the pandemic in the region and situate the window of the WHO declaration within the broader history. Third, we aim to provide historical context for the course of the pandemic in Central Asia.

methodsTraditional surveillance metrics, including counts and rates of COVID-19 transmissions and deaths, and enhanced surveillance indicators, including speed, acceleration, jerk, and persistence, were used to measure shifts in the pandemic. To identify the appearance and duration of variants of concern, we used data on sequenced SARS-CoV-2 variants from the Global Initiative on Sharing All Influenza Data (GISAID). We used Nextclade nomenclature to collect clade designations from sequences and Pangolin nomenclature for lineage designations of SARS-CoV-2. Finally, we conducted a 1-sided t test to determine whether regional speed was greater than an outbreak threshold of 10. We ran the test iteratively with 6 months of data across the sample period.

resultsSpeed for the region had remained below the outbreak threshold for 7 months by the time of the WHO declaration. Acceleration and jerk were also low and stable. Although the 1- and 7-day persistence coefficients remained statistically significant, the coefficients were relatively small in magnitude (0.125 and 0.347, respectively). Furthermore, the shift parameters for either of the 2 most recent weeks around May 5, 2023, were both significant and negative, meaning the clustering effect of new COVID-19 cases became even smaller in the 2 weeks around the WHO declaration. From December 2021 onward, Omicron was the predominant variant of concern in sequenced viral samples. The rolling t test of speed equal to 10 became entirely insignificant for the first time in March 2023.

conclusionsAlthough COVID-19 continues to circulate in Central Asia, the rate of transmission remained well below the threshold of an outbreak for 7 months ahead of the WHO declaration. COVID-19 appeared to be endemic in the region and no longer reached the threshold of a pandemic. Both standard and enhanced surveillance metrics suggest the pandemic had ended by the time of the WHO declaration.

Indexed as

COVID-19PandemicsAsiaAsia, CentralHistory, 21st CenturyHumansSARS-CoV-27-day lagaccelerationArellano-BondArmeniaAzerbaijanCentral AsiaCOVID-19COVID-19 transmissionCyprusdecelerationdynamic panelFaeroe Islandsgeneralized method of momentsGeorgiaGibraltarGMMjerkKazakhstanKosovoKyrgyzstanMacedoniapandemicpublic healthRussiaSARS-CoV-2speedsurveillanceTajikistan TurkeyTurkmenistanUzbekistan

Identifiers

PMID39013115
PMCPMC11391161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.